
    
      This is a Phase 1, nonrandomized study to evaluate the cardiac safety of TAS-102 in patients
      with advanced solid tumors. The study is conducted in 2 phases: the cardiac safety evaluation
      phase to investigate cardiac repolarization and the cardiac safety profile (Cycle 1) and the
      extension phase to assess the safety profile and antitumor activity (subsequent cycles).
    
  